<DOC>
	<DOCNO>NCT01891487</DOCNO>
	<brief_summary>This study research safety efficacy Bimatoprost 0.03 % soultion versus placebo apply eyebrow treatment thin eyebrow . This 36 week study Bimatoprost 0.03 % solution/placebo apply daily subject eyebrow duration study .</brief_summary>
	<brief_title>Safety Efficacy Bimatoprost 0.03 % Solution Treatment Thinning Eyebrows</brief_title>
	<detailed_description>A parallel , placebo-controlled , single-center , prospective , randomize , double blind , pilot trial demonstrate bimatoprost 0.03 % efficacy eyebrow hypotrichosis otherwise healthy individual thin eyebrow . Bimatoprost 0.03 % placebo apply eyebrow margin daily 36 week . Adverse event assess , subject complete outcome questionnaire study visit . Eyebrow growth darken score investigator photography take study visit . Eyebrows generally compose three type hair : fine vellus hair small , second type slightly large , lightly pigment hair . The supercilia large terminal hair visible primarily responsible color shape brow . Eyelashes compose terminal hair , well demonstrate bimatoprost application hair render longer , thicker darker ( Allergan Protocol 192024-032 ) . It also demonstrate bimatoprost darken vellus hair , make visible . It may administer bimatoprost eyebrow cause terminal hair become longer , thicker darker , make vellus lightly pigment hairs become noticeable , thus increase intensity fullness entire brow . Multiple study conduct assess safety efficacy application bimatoprost solution eyelid growth natural eyelash ( Yoelin S , et al , 2010 ) . In 2 active-controlled phase 3 study LUMIGAN速 , eyelash growth report adverse event 3 month treatment subject receive bimatoprost daily ( Allergan Studies 192024-008 192024-009 ) . The application bimatoprost solution eyelid proven effective enhance eyelash growth woman apply daily 12 week ( Cohen JL , 2010 ) . This drug effect formally acknowledge LUMIGAN速 package insert ( Appendix 5.2 ) support bimatoprost 's effect eyelash growth . The package insert indicate LUMIGAN速 may gradually change eyelash regard increase length , thickness , pigmentation , number eyelash . Since US approval 2001 , several adverse event `` growth eyelash '' report conjunction use LUMIGAN速 . Subjects randomize Track A , active study drug , bimatoprost 0.03 % solution , Track B , placebo . Each track apply dose , 1 drop per eyebrow daily , determine safety efficacy bimatoprost 0.03 % solution versus placebo .</detailed_description>
	<mesh_term>Hypotrichosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<criteria>Females male , age 1875 year brows naturally thin score 1 ( thin ) 2 ( thin ) baseline determine Investigator Global Eyebrow Assessment ( IGEA ) . Subjects agree forgo additional treatment brow , wax , pluck , thread and/or tint duration study . Desires participate research study Any uncontrolled systemic disease . Any known disease abnormality eyelid eyebrow . Known allergy reaction bimatoprost placebo ingredient . Pregnancy . Subjects thin brow result plucking , trichotillomania , chemotherapy condition treatment cause hair loss . Subjects use counter prescription eyebrow growth product 3 month prior baseline . Subjects tattooed eyebrow and/or permanent semipermanent tint dye within 3 month prior baseline . Subjects score 3 4 eyebrow scale . Current enrollment investigational drug device study participation study 30 day prior baseline . Subjects use prostaglandin analog treatment high intraocular pressure . Aphakic subject and/or pseudophakic subject torn posterior lens capsule . Subjects know risk factor macular edema .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Eyebrow</keyword>
	<keyword>Hypotrichosis</keyword>
	<keyword>Thinning</keyword>
	<keyword>Bimatoprost</keyword>
</DOC>